H. Lundbeck A/S (CPH:HLUN.B)
42.56
-0.08 (-0.19%)
Sep 18, 2026, 4:59 PM CET
H. Lundbeck Employees
H. Lundbeck had 5,000 employees as of June 30, 2026. The number of employees decreased by 700 or -12.28% compared to the same quarter last year.
Employees
5,000
Change
-700
Growth
-12.28%
Revenue / Employee
5.19M DKK
Profits / Employee
787.00K DKK
Market Cap
41.78B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 5,000 | -700 | -12.28% |
| Mar 31, 2026 | 5,000 | -700 | -12.28% |
| Dec 31, 2025 | 5,039 | -404 | -7.42% |
| Sep 30, 2025 | 5,700 | 200 | 3.64% |
| Jun 30, 2025 | 5,700 | -100 | -1.72% |
| Mar 31, 2025 | 5,700 | 0 | - |
| Dec 31, 2024 | 5,443 | -238 | -4.19% |
| Sep 30, 2024 | 5,500 | -200 | -3.51% |
| Jun 30, 2024 | 5,800 | 200 | 3.57% |
| Mar 31, 2024 | 5,700 | 200 | 3.64% |
| Dec 31, 2023 | 5,681 | 231 | 4.24% |
| Sep 30, 2023 | 5,700 | 248 | 4.55% |
| Jun 30, 2023 | 5,600 | 163 | 3.00% |
| Mar 31, 2023 | 5,500 | 147 | 2.75% |
| Dec 31, 2022 | 5,450 | 102 | 1.91% |
| Sep 30, 2022 | 5,452 | -136 | -2.43% |
| Jun 30, 2022 | 5,437 | -166 | -2.96% |
| Mar 31, 2022 | 5,353 | -198 | -3.57% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novo Nordisk | 66,700 |
| Demant | 26,616 |
| Coloplast | 17,213 |
| GN Store Nord | 7,744 |
| Ambu A/S | 5,200 |
| Embla Medical | 4,500 |
| Genmab | 3,119 |
| ALK-Abelló | 2,773 |
H. Lundbeck News
- 3 days ago - Lundbeck Receives Marketing Authorization For Vyepti In Japan For The Prevention Of Migraine Attacks - Nasdaq
- 4 days ago - Lundbeck Completes DEEp SEA Randomization; Phase III Bexicaserin Trial In Dravet Syndrome Advances - Nasdaq
- 4 days ago - Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome - PRNewsWire
- 8 days ago - Lundbeck Secures FDA Orphan Drug Designation For Asedebart In Cushing's Syndrome - Nasdaq
- 8 days ago - The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome - PRNewsWire
- 26 days ago - European Commission Grants Orphan Designation For Lundbeck's Asedebart For Cushing's Syndrome - Nasdaq
- 4 weeks ago - H. Lundbeck Quarterly report: Q2 2026 - Filings
- 4 weeks ago - H. Lundbeck Slides: Q2 2026 - Filings